Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns – A New Future
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Effective treatment for functional disability caused by essential tremor is a significant unmet need faced by many clinicians today. Current literature regarding focal therapy by botulinum toxin type A (BoNT-A) injections uses fixed dosing regimens, which cannot be individualized, provides only limited functional benefit and unacceptable muscle weakness commonly occurs. This 38-week open label study, the longest to-date, demonstrates how kinematic technology addressed all these issues by guiding muscle selection. METHOD: Participants (n = 24) were assessed at weeks 0, 6, 16, 22, 32, and 38 and injected with incobotulinumtoxinA at weeks 0, 16, and 32. Clinical assessments including UPDRS tremor items, Fahn-Tolosa-Marin (FTM) tremor rating scale assessing tremor severity, writing and functional ability, quality of life questionnaire (QUEST) and objective kinematic assessments were completed at every visit. Participants performed two postural and two weight-bearing scripted tasks with motion sensors placed over the wrist, elbow and shoulder joints. These sensors captured angular tremor amplitude (RMS units) and acceleration joint motion that was segmented into directional components: flexion-extension (F/E), pronation-supination and radial-ulnar at the wrist, F/E at the elbow, and F/E and adduction-abduction at the shoulder. Injection parameters were determined using kinematics, followed by the clinician's determination of which muscles would contribute to the specific upper limb tremor biomechanics and dosing per participant. RESULTS: Multi-joint biomechanical recordings allowed individualized muscle selection and showed significant improvement in whole-arm function, FTM parts A-C scores, at week 6 which continued throughout the study. By week 38, the total FTM score statistically significantly reduced from 16.2±4.6 at week 0 to 9.5±6.3 (p<0.0005). UPDRS item 21 score rating action tremor was significantly reduced from 2.6±0.5 at week 0 to 1.6±1.1 (p = 0.01) at week 32. Quality of life (QUEST) significantly improved from 40.3±15.8 at week 0 to 31.1±15.3 (p = 0.035) at week 32 and to 27.8±15.3 (p = 0.028) at week 38. Kinematics provided an objective, secondary outcome measure, which showed a significant decrease in tremor amplitude in the wrist and shoulder joints (p<0.05). Eight participants (40%) self-reported mild weakness in injected muscles but had no interference in arm function. CONCLUSION: Kinematic tremor assessments provide the injector unique insight to objectively individualize and personalize injection parameters demonstrating BoNT-A effectively alleviates functional disability caused by essential tremor. Kinematic technology is a promising method for standardizing assessments and for focal upper limb tremor treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT02427646.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The participants recruited met the inclusion/exclusion criteria35,39.”
From PHTNet: Characterization and Deep Mining of Involuntary Pathological Hand Tremor using Recurrent Neural Network Models (2020) · cites this paper as [39]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frequency Dependence of Signal Power and Spatial Reach of the Local Field Potential
Leski, S., Lindén, H., Tetzlaff, T., Pettersen, K. H., & Einevoll, G. T. (2013) · PubMed · doi:10.18154/rwth-conv-084442 · Cited by 3,639
Treatment of patients with essential tremor
Deuschl, G., Raethjen, J., Hellriegel, H., & Elble, R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70322-7 · Cited by 428 · cited 2×
“ET patients who seek treatment suffer from functionally disabling tremor which restricts performance of every-day activities [1].”
BackgroundZesiewicz, T. A., Elble, R., Louis, E. D., Hauser, R. A., Sullivan, K. L., Dewey, R. B., Ondo, W. G., Gronseth, G. S., & Weiner, W. J. (2005) · Neurology · doi:10.1212/01.wnl.0000163769.28552.cd · Cited by 371 · cited 2×
“Despite this modest clinical benefit, BoNT-A therapy has not been widely adopted due to risk of significant hand and wrist weakness causing functional limb impairment [7].”
BackgroundJankovic, J., Schwartz, K., & Donovan, D. T. (1990) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.8.633 · Cited by 353 · cited 2×
“As 30% of patients do not respond to standard pharmacological medication and yet another 30% who start drug therapy will discontinue treatment due to side effects, an effective tremor therapy is needed [4,6].”
BackgroundJankovic, J., Schwartz, K., Clemence, W., Aswad, A., & Mordaunt, J. (1996) · Movement Disorders · doi:10.1002/mds.870110306 · Cited by 235 · cited 1×
“Selection of tremulous muscles has previously been established by using a fixed method, injecting only flexor and extensor wrist muscles [10,18,19], by using single joint surface EMG electrodes [8], or by combining accelerometry and surface EMG [11].”
MethodA randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor
Brin, M. F., Lyons, K. E., Doucette, J., Adler, C. H., Caviness, J. N., Comella, C. L., Dubinsky, R. M., Friedman, J. H., Manyam, B. V., Matsumoto, J. Y., et al. (2001) · Neurology · doi:10.1212/wnl.56.11.1523 · Cited by 233 · cited 3×
“Sample size was similar to previous literature [10,19].”
BackgroundMethodResultAcute and chronic effects of propranolol and primidone in essential tremor
Koller, W. C., & Vetere-Overfield, B. (1989) · Neurology · doi:10.1212/wnl.39.12.1587 · Cited by 198
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond
Baizabal-Carvallo, J. F., Kagnoff, M. N., Jimenez-Shahed, J., Fekete, R., & Jankovic, J. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-304943 · Cited by 181 · cited 1×
“Surgical therapy by thalamotomy or by unilateral/bilateral thalamic deep brain stimulation is safe, although possibly effective (Level C recommendation) and is performed in patients under the age of 75 where post-operative device programming remains unclear [2,5].”
BackgroundBotulinum toxin treatment of tremors
Jankovic, J., & Schwartz, K. (1991) · Neurology · doi:10.1212/wnl.41.8.1185 · Cited by 152
Approach to the Treatment of Limb Disorders With Botulinum Toxin A: Experience With 187 Patients
Pullman, S. L. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550070055012 · Cited by 124
Cited by
Samotus, O., Lee, J., & Jog, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178670 · Cited by 72
“This clinical phase II pilot study protocol, previously described in Samotus et al 2016 and in Rahimi et al in 2015, was approved by the Western University Health Sciences Research Ethics Board as an open label, single-centre, single-injector study (Health Canada CTA# 178589) on March 28, 2012…”
MethodSelf-citationTreatment of essential tremor: current status
Sharma, S., & Pandey, S. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136647 · Cited by 66
Botulinum Toxin for the Treatment of Hand Tremor
Niemann, N., & Jankovic, J. J. (2018) · Toxins · doi:10.3390/toxins10070299 · Cited by 57
Botulinum toxin for the treatment of tremor
Mittal, S. O., Lenka, A., & Jankovic, J. J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.01.023 · Cited by 60
Assessment of movement disorders using wearable sensors during upper limb tasks: A scoping review
Vanmechelen, I., Haberfehlner, H., Vleeschhauwer, J. D., Wonterghem, E. V., Feys, H., Desloovere, K., Aerts, J., & Monbaliu, E. (2023) · Frontiers in Robotics and AI · doi:10.3389/frobt.2022.1068413 · Cited by 61
Metadata
- Authors
- Samotus, O., Rahimi, F., Lee, J., & Jog, M.
- Affiliations
- Western University (CA)
- University of Bonab (IR)
- Lawson Health Research Institute (CA)
- Corresponding author
- Jog, Mandar
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-21
- Volume
- 11
- Issue
- 4
- Pages
- e0153739
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4839603
- OpenAlex
- W2339108496
- Cited by
- 46
- References
- 22
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 8 · 2019: 9 · 2018: 4 · 2017: 3
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Merz Pharma (R.14.022/18445)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Keywords
- essential tremor, incobotulinumtoxinA, botulinum toxin type A, kinematic assessment, upper limb tremor, individualized dosing, muscle selection, functional capacity, quality of life, tremor severity, motion sensors, focal therapy, Unified Parkinson's Disease Rating Scale
- MeSH terms
- Aged, Biomechanical Phenomena, Female, Humans, Male, Neuromuscular Agents, Botulinum Toxins, Type A, Essential Tremor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns – A New Future. https://app.cochat.ai/papers/10.1371/journal.pone.0153739
- The paper
- Samotus, O., Rahimi, F., Lee, J., & Jog, M. (2016). Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns – A New Future. PLOS ONE. https://doi.org/10.1371/journal.pone.0153739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.